TG Therapeutics - TGTX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $26.00
  • Forecasted Upside: 96.52%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$13.23
▼ -0.6 (-4.34%)

This chart shows the closing price for TGTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New TG Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TGTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TGTX

Analyst Price Target is $26.00
▲ +96.52% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for TG Therapeutics in the last 3 months. The average price target is $26.00, with a high forecast of $45.00 and a low forecast of $12.00. The average price target represents a 96.52% upside from the last price of $13.23.

This chart shows the closing price for TGTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 polled investment analysts is to moderate buy stock in TG Therapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/30/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/28/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/26/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/27/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/25/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/23/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/22/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/5/2024B. RileyBoost TargetBuy ➝ Buy$24.00 ➝ $29.00Low
1/11/2024HC WainwrightBoost TargetBuy ➝ Buy$41.00 ➝ $45.00Low
11/1/2023Jefferies Financial GroupReiterated RatingBuy ➝ Buy$23.00Low
11/1/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$22.00 ➝ $23.00Low
10/20/2023B. RileyLower TargetBuy ➝ Buy$32.00 ➝ $24.00Low
9/18/2023HC WainwrightReiterated RatingBuy ➝ Buy$41.00Low
8/7/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$34.00 ➝ $22.00Low
8/2/2023The Goldman Sachs GroupUpgradeSell ➝ Neutral$16.00 ➝ $12.00N/A
8/1/2023B. RileyReiterated RatingBuy ➝ Buy$42.00 ➝ $32.00Low
8/1/2023HC WainwrightBoost TargetBuy ➝ Buy$34.00 ➝ $41.00N/A
7/24/2023The Goldman Sachs GroupBoost TargetSell$10.00 ➝ $16.00Low
7/13/2023B. RileyReiterated RatingBuy ➝ Buy$42.00Low
4/17/2023Cantor FitzgeraldReiterated RatingOverweight$24.00N/A
4/14/2023HC WainwrightReiterated RatingBuy$24.00 ➝ $28.00Low
3/31/2023HC WainwrightReiterated RatingBuy$24.00Low
3/1/2023HC WainwrightReiterated RatingBuy$24.00Low
2/7/2023Cantor FitzgeraldBoost TargetOverweight$18.00 ➝ $24.00Low
1/24/2023Evercore ISIBoost TargetOutperform$16.00 ➝ $25.00Low
12/30/2022Evercore ISIBoost TargetOutperform$11.00 ➝ $16.00Low
12/30/2022The Goldman Sachs GroupBoost TargetSell$4.00 ➝ $6.00Low
12/30/2022B. RileyBoost TargetBuy$17.00 ➝ $23.00Low
12/29/2022HC WainwrightBoost TargetBuy$19.00 ➝ $24.00Low
12/29/2022Bank of AmericaBoost TargetUnderperform$5.00 ➝ $6.00Low
6/13/2022B. RileyLower TargetBuy$23.00 ➝ $17.00Low
5/20/2022Bank of AmericaInitiated CoverageUnderperformHigh
5/9/2022Cantor FitzgeraldReiterated RatingOverweightHigh
4/19/2022B. RileyLower TargetBuy$35.00 ➝ $23.00High
4/18/2022HC WainwrightLower TargetBuy$68.00 ➝ $19.00High
4/1/2022Cantor FitzgeraldReiterated RatingOverweightN/A
2/23/2022B. RileyLower TargetBuy$49.00 ➝ $35.00High
1/24/2022HC WainwrightLower TargetBuy$75.00 ➝ $70.00High
12/1/2021Evercore ISILower TargetOutperform$55.00 ➝ $36.00Low
12/1/2021HC WainwrightLower TargetBuy$84.00 ➝ $75.00High
12/1/2021The Goldman Sachs GroupLower TargetSell$26.00 ➝ $13.00High
11/15/2021The Goldman Sachs GroupDowngradeNeutral ➝ Sell$33.00 ➝ $26.00High
11/7/2021Evercore ISIReiterated RatingBuyMedium
8/2/2021HC WainwrightLower TargetBuy$89.00 ➝ $84.00High
4/20/2021The Goldman Sachs GroupInitiated CoverageNeutral$50.00High
4/19/2021HC WainwrightBoost TargetBuy$79.00 ➝ $89.00High
2/8/2021HC WainwrightBoost TargetBuy$78.00 ➝ $79.00Medium
2/5/2021B. RileyBoost TargetBuy$90.00 ➝ $95.00High
1/19/2021HC WainwrightBoost TargetBuy$61.00 ➝ $78.00Low
12/10/2020HC WainwrightBoost TargetBuy$38.00 ➝ $61.00High
10/28/2020Cantor FitzgeraldBoost TargetOverweight$30.00 ➝ $48.00Low
9/1/2020JPMorgan Chase & Co.Initiated CoverageOverweight$38.00High
8/11/2020HC WainwrightBoost TargetBuy$32.00 ➝ $38.00Medium
8/10/2020B. RileyReiterated RatingBuy$37.00Medium
6/15/2020B. RileyReiterated RatingBuy$37.00Low
6/5/2020Evercore ISIInitiated CoverageOutperform$60.00High
6/1/2020B. RileyReiterated RatingBuy$37.00High
5/29/2020HC WainwrightReiterated RatingBuyHigh
5/18/2020HC WainwrightReiterated RatingBuy$32.00Medium
5/17/2020B. RileyBoost TargetBuy$29.00 ➝ $37.00Medium
5/12/2020HC WainwrightReiterated RatingBuy$32.00Medium
5/6/2020Cantor FitzgeraldBoost TargetOverweight$19.00 ➝ $35.00High
5/6/2020B. RileyBoost TargetBuy$25.00 ➝ $29.00High
5/5/2020HC WainwrightBoost TargetBuy$24.00 ➝ $32.00High
4/17/2020B. RileyReiterated RatingBuy$25.00High
1/17/2020HC WainwrightBoost TargetBuy$20.00 ➝ $24.00High
12/10/2019HC WainwrightReiterated RatingBuy$20.00High
11/27/2019B. RileyInitiated CoverageBuy$12.00High
11/12/2019HC WainwrightReiterated RatingBuy$20.00Medium
10/28/2019HC WainwrightReiterated RatingBuy$20.00Medium
6/11/2019B. RileyReiterated RatingBuyMedium
5/13/2019Cantor FitzgeraldReiterated RatingBuy$17.00High
4/12/2019HC WainwrightReiterated RatingBuy$20.00Low
3/29/2019Cantor FitzgeraldInitiated CoverageOverweight$17.00High
(Data available from 2/21/2019 forward)

News Sentiment Rating

0.74 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 12 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/26/2023
  • 6 very positive mentions
  • 22 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
8/25/2023
  • 8 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/24/2023
  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/24/2023
  • 4 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/23/2023
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/23/2023
  • 1 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/22/2024
  • 11 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/21/2024

Current Sentiment

  • 11 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
TG Therapeutics logo
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
Read More

Today's Range

Now: $13.23
Low: $13.17
High: $13.86

50 Day Range

MA: $16.40
Low: $13.23
High: $21.30

52 Week Range

Now: $13.23
Low: $6.46
High: $35.67

Volume

3,872,754 shs

Average Volume

5,150,837 shs

Market Capitalization

$2.00 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.42

Frequently Asked Questions

What sell-side analysts currently cover shares of TG Therapeutics?

The following Wall Street sell-side analysts have issued reports on TG Therapeutics in the last year: B. Riley, Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., StockNews.com, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for TGTX.

What is the current price target for TG Therapeutics?

6 Wall Street analysts have set twelve-month price targets for TG Therapeutics in the last year. Their average twelve-month price target is $26.00, suggesting a possible upside of 96.5%. HC Wainwright has the highest price target set, predicting TGTX will reach $45.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $12.00 for TG Therapeutics in the next year.
View the latest price targets for TGTX.

What is the current consensus analyst rating for TG Therapeutics?

TG Therapeutics currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for TGTX.

What other companies compete with TG Therapeutics?

How do I contact TG Therapeutics' investor relations team?

TG Therapeutics' physical mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company's listed phone number is (212) 554-4484 and its investor relations email address is [email protected]. The official website for TG Therapeutics is www.tgtherapeutics.com. Learn More about contacing TG Therapeutics investor relations.